By Dawn Owen, MD, PhD, and Megan Daly, MD, co-chairs of the Continuum of Care of Non-resectable NSCLC Planning Committee
ASTRO is excited to present a live, interactive webinar series on non-resectable, locally advanced non-small cell lung cancer (NSCLC). The Continuum of Care of Non-resectable NSCLC series is a three-part webinar supported by an independent medical education grant from AstraZeneca and is free to registered participants.
There is a wide gap between the near-universal expert recommendation for multidisciplinary care and the penetration of this model of care delivery into real world clinical care environments. Most examples of multidisciplinary care programs exist in academic or managed care environments, but over 70% of lung cancer care in the United States is delivered outside such settings (Little, 2007). Even within environments with multidisciplinary care programs, close examination reveals no consistent model structure or function and little evidence to support the impact (Osarogiagbon, 2016). It becomes imperative to increase awareness and understanding for the diagnosis and treatment of lung cancer.
This webinar series provides a case-based approach to the diagnosis, workup and treatment of NSCLC with a specific focus on the paradigm of chemoradiation and adjuvant durvalumab. The webinar series offers continuing education credits and SA-CME credits.
The first webinar, scheduled for Thursday, July 15, at 6:00 p.m. Eastern time and titled “Overcoming Barriers to Care,” features a multi-institutional multidisciplinary tumor board comprising a radiation oncologist, medical oncologist, thoracic surgeon and pulmonologist. This panel will take you through the process for the staging of lung cancer and the multidisciplinary discussion that follows for deciding if a patient is unresectable.
The second webinar is scheduled for Wednesday, July 21, at 6:00 p.m. Eastern time and titled “Best Practices for the Continuum of Care.” This session will take you through the interdisciplinary coordination of chemotherapy and radiation. You will hear about the steps that a medical oncologist and radiation oncologist take to decide on type of chemotherapy, whether a patient is a radiation candidate, and the identification and management of pneumonitis in the durvalumab era.
The third and final installation in this series (in August, date TBD), will focus on challenging unresectable cases with a multidisciplinary panel that includes radiation oncology, medical oncology, medical physics, pulmonology and dosimetry. Topics, such as the controversial role of proton therapy for lung cancer, management of patients with cardiac/lung/autoimmune comorbidities and the role of induction systemic therapy, will be broached.
The three webinars in this series are designed to actively engage the audience, and the audience is invited to proffer questions in the comment section of this blog or in real time. Review the agenda and register today for these forum case discussions in order to participate in a multidisciplinary lung tumor board-style review.